Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck

BACKGROUND: Concurrent chemoradiotherapy is an established component of the nonoperative management of locally advanced head and neck squamous cell carcinoma (HNSCC), but the standard dose of 100 mg/m(2) cisplatin every 3 weeks is associated with clinically significant toxicity. Interest in a more t...

Full description

Saved in:
Bibliographic Details
Published in:J Natl Cancer Inst
Main Authors: Bauml, Joshua M, Vinnakota, Ravi, Anna Park, Yeun-Hee, Bates, Susan E, Fojo, Tito, Aggarwal, Charu, Limaye, Sewanti, Damjanov, Nevena, Di Stefano, Jessica, Ciunci, Christine, Genden, Eric M, Wisnivesky, Juan P, Ferrandino, Rocco, Mamtani, Ronac, Langer, Corey J, Cohen, Roger B, Sigel, Keith
Format: Artigo
Language:Inglês
Published: Oxford University Press 2018
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510226/
https://ncbi.nlm.nih.gov/pubmed/30239887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djy133
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items